^
Association details:
| Biomarker: | PRKDC mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prevalence of prkdc mutations and association with response to immune checkpoint inhibitors in solid tumors
Published date:
05/13/2020
Excerpt:
...In ICIs-treated cohorts, we also found the PRKDC mutation was associated with superior survival (median PFS, not reached (NR) vs. 6.8 months HR, 0.2893 95% CI, 0.1255-0.6672 P = 0.0650, Hellmann cohort; median OS, 1184 days vs. 250 days HR, 0.5126 95% CI, 0.2715-0.9679 P = 0.1020, Allen cohort), and the superiority was significantly in multivariate Cox regression analyses...PRKDC mutations are associated with an increased TMB, an inflamed TME and a better response to ICIs...
DOI:
10.1200/JCO.2020.38.15_suppl.e15071